Research location
Seville
Seville, Spain
Advertisement
Research activity in Seville
Seville, SpainCureCurrent currently publishes aggregate city-level research activity for this location: 21 trials and 28 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Seville
21 linked trials · page 1 of 1A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)NCT07680764 · 2026-09-10 · 1 site observation
RECRUITING
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1NCT06767514 · 2025-02-27 · 1 site observation
RECRUITING
Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)NCT07680790 · 2026-09-30 · 1 site observation
NOT_YET_RECRUITING
Study of the Performance of the GLUCUBE System in Patients With Type 2 DiabetesNCT07075796 · 2025-06-02 · 1 site observation
COMPLETED
Evaluation of Prevalence and Risk Factors of Persistent COVID-19 in Immunocompromised PatientsNCT06576102 · 2024-03-01 · 1 site observation
COMPLETED
Deciphering the Role of Dietary Fatty Acids on Extracellular Vesicles-mediated Intercellular CommunicationNCT06051461 · 2023-11-01 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid TumorsNCT05551117 · 2023-06-13 · 1 site observation
TERMINATED
Safety and Efficacy of Melatonin in Patients With Multiple Progressive Primary SclerosisNCT03540485 · 2019-11-29 · 3 site observations
TERMINATED
Screening for Cancer in Patients With Unprovoked VTENCT03937583 · 2019-10-23 · 1 site observation
UNKNOWN
Randomized CT to Evaluate Efficacy of Neoadjuvant Chemotherapy Customized by Levels of BRCA1-HER2 Negative Breast CancerNCT02365805 · 2014-04-01 · 3 site observations
COMPLETED
Changes in Liver Steatosis After Switching to Raltegravir in HIV/HCV CoinfectionNCT01900015 · 2014-02-03 · 1 site observation
COMPLETED
Pharmacokinetic Interactions Between Telaprevir and Un-boosted AtazanavirNCT01818856 · 2012-12-01 · 1 site observation
COMPLETED
VERifynow in DIabetes Non-responsiveness: a Study on Switching From Clopidogrel to PrasugrelNCT01684813 · 2012-10-01 · 1 site observation
COMPLETED
Efficacy of Pegylated Interferon Plus Ribavirin Plus Nitazoxanide in HCV Genotype 4 and HIV CoinfectionNCT01529073 · 2012-02-01 · 1 site observation
UNKNOWN
Conventional Laparoscopic Sleeve Gastrectomy Versus Endograb-assisted Single-port Sleeve GastrectomyNCT02023294 · 2011-04-01 · 1 site observation
COMPLETED
Influence of Nevirapine on HCV Viral LoadNCT01277627 · 2011-01-01 · 1 site observation
UNKNOWN
Human Adipose Derived Mesenchymal Stem Cells for Critical Limb Ischemia (CLI) in Diabetic PatientsNCT01257776 · 2010-12-01 · 2 site observations
COMPLETED
A Mediterranean-style Breakfast and Postprandial Lipid Disorders in Obese Pre-adolescents and AdultsNCT01518803 · 2010-05-01 · 1 site observation
COMPLETED
Darunavir Levels, Virological Efficacy, Proviral ADN and Resistances in Patients on Darunavir/Ritonavir MonotherapyNCT01606722 · 2010-01-01 · 1 site observation
COMPLETED
Autologous Bone Marrow Derived Mononuclear Cells in Treating Diabetic Patients With Critical Limb IschemiaNCT00872326 · 2007-12-01 · 1 site observation
COMPLETED
Incidence and Severity of Neuropsychiatric Adverse Events of Efavirenz Given as a Stepped Dosage vs. the Usual DosageNCT00556634 · 2006-04-01 · 3 site observations
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.